

# SBRT: prescription, planning, delivery

# pietro.mancosu@humanitas.it

# Index

AAPM recommendation

Italian SBRT-WG

Same Gray?

Multiplanning experiences

**Output Factor** 

Take home messages



HUMANITAS

# AAPM 101 Recommendations

# Simulation imaging:

- Precise delineation of patient anatomy, targets.....
- $\downarrow$  CT + MR + PET/CT
- Scan length: at least 5-10 cm superior and inferior..
- **4** CT slice thickness: 1-3 mm.
- 4 4DCT or breath-hold techiniques.

# **Treatment planning:**

- ↓ ICRU 50 and 62 definitions for GTV, CTV, PTV and OAR.
- **4** Use of multiple non overlapping beams: ... IMRT, VMAT.
- **4** 6 MV photon beam...beam penetration and penombra
- 4 5 mm MLC leaf width is adequate for most applications.

# Calculation grid size and algorithm:

Use of an isotropic grid of 2 mm o finer.
 Use of convolution/superposition algorithms. No Pencil Beam!

# Patient positioning, immobilization:

Body frames and fiducial systems, abdominal compression...
Image guided localization: ..Epid, 3D kV CBCT, ultrasound ecc.
Respiratory motion management.

# Normalization/Prescribing Dose:

Various options are available:

Isocenter, %IDL: 80%, 65%, 60%, 50%, PTV periphery ...

# Italy of the towers

# <image>

San Giminiano 1300 d.C. 72 towers 2000 abitants

**HUMANITAS** 


CANCER CENTER





# AIFM SBRT WG

SABRIphys II – Stereotectic Ablative Body Radiotherapy Italian physicist working group



Objective 1: Sharing of personal knowledge

Objective 2: Scientific studies and write scientific papers

Objective 3: Seminars and schools



HUMANITAS

# Scientific publications

HUMANITAS CANCER CENTER



# 21 papers (2015-2019): 3 letters to the editor; 5 reviews; 13 full papers 6 papers in preparation/under review Best paper EJMP 2017 Focus session EJMP: Physics of lung SBRT(2018)

# Courses





UNIVERSITÀ DEGLI STUDI



24/25 OTTOBRE 2014 Università degli studi di Milano STEREOTACTIC BODY RADIATION THERAPY

Implementazione, Sostenibilità, Avanzamento Tecnologico e Risultati a Confronto



# Stereotactic B Radiation The

Successi e Prospettive F II edizione

7-8 Novembre 2016 Roma

# Associazione Italiana Radioterapia e Oncolo Endorsed by:





# STEREOTACTIC BODY RADIATION THERAPY: FROM PHYSICS TO CLINIC

FLORENCE (Italy) • October 4-6, 2018

Course directors: Filippo Alongi, Verona - Pietro Mancosu, Milan

# CONGRESSO NAZIONALE

PALACONGRESSI - Rimini, 7-10 novembre

# NEW: Basis of SBRT for physicists AIFM/Caldirola March 2020

Introduction: why knowledge sharing?



#RadOnc

# https://twitter.com/BreastDocUK/status/805672034239913986?s=08 Dec 5, 2016

# Current Issues with radiotherapy provision in England

HUMANITAS

•	Competition	Variatio	on in quality
•	Isolated practice	Comm	on protocols not used
•	Innovation and expertise	Variatio	on in availability of specialist staff
	exist in both small and	Variatio	on in use of modernised equipment
	large centres	Variabl	e patient access to trials
•	Lack of sharing	Lack of	outcomes measurement
		Variabl	e leadership
		Low pa	tient throughput for some cancer types
		. 3,4 or r	nore Clinical Oncologist subspecialisations
		0. Variabl	e clinical QA

# Do we have the same Gray?

### HUMANITAS CANCER CENTER






































# Multicenter planning: liver

# Best paper



# Multicentre treatment planning inter-comparison in a national context: The liver stereotactic ablative radiotherapy case


Marco Esposito <sup>a</sup>, Giulia Maggi <sup>b</sup>, Carmelo Marino <sup>c</sup>, Laura Bottalico <sup>d</sup>, Elisabetta Cagni <sup>e</sup>, Claudia Carbonini <sup>f</sup>, Michelina Casale <sup>g</sup>, Stefania Clemente <sup>h</sup>, Valentina D'Alesio <sup>d</sup>, David Fedele <sup>i</sup>, Francesca Romana Giglioli <sup>j</sup>, Valeria Landoni <sup>k</sup>, Anna Martinotti <sup>1</sup>, Roberta Nigro <sup>m</sup>, Lidia Strigari <sup>k,\*</sup>, Elena Villaggi <sup>n</sup>, Pietro Mancosu <sup>b</sup>



12 centers; 5 liver cases Common protocol 75 Gy – 25Gy x 3 fr V95%>95% (at least 67%)

HUMANITAS

PTV




# Multicenter planning: prostate



# A feasibility dosimetric study on prostate cancer

Are we ready for a multicenter clinical trial on SBRT?

Carmelo Marino · Elena Villaggi · Giulia Maggi · Marco Esposito · Lidia Strigari · Elisa Bonanno · Giusi R. Borzì · Claudia Carbonini · Rita Consorti · David Fedele · Christian Fiandra · Isidora Ielo · Tiziana Malatesta · Maria Rosa Malisan · Anna Martinotti · Renzo Moretti · Barbara Nardiello · Caterina Oliviero · Stefania Clemente · Pietro Mancosu




14 centers 5 prostate cases Same contours Common protocol 35 Gy – 7Gy x 5 fr

HUMANITAS

# Multicenter planning: prostate





Mean DVH values over the 5 patients for the 14 centers

# Multicenter planning: prostate




Fig. 4 Planning target volume DVH for prostate patient 5 for a the first optimization and b the second optimization

Replanned based on the mean values

HUMANITAS


CANCER CENTER



**U** 

## Plan quality improvement by DVH sharing and planner's experience: results of a SBRT multicentric planning study on prostate

Villaggi Elena<sup>(1)</sup>, Hernandez Victor<sup>(2)</sup>, Fusella Marco<sup>(3)</sup>, Moretti Eugenia<sup>(4)</sup>, Russo Serenella<sup>(5)</sup>, Vaccara Elena Maria Luisa<sup>(6)</sup>, Nardiello Barbara<sup>(7)</sup>, Esposito Marco<sup>(5)</sup>, Saez Jordi<sup>(8)</sup>, Cilla Savino<sup>(9)</sup>, Marino Carmelo<sup>(10)</sup>, Stasi Michele<sup>(11)</sup>, Mancosu Pietro<sup>(12)</sup>



# To be or not to be homogeneous?




Fig. 3 Presentation of the average homogeneity and conformity indices for all patients using a network map [20], separated by participating institution. *inst.* Institution, *IMAT* intensity-modulated arc therapy, *3DCRT* three-dimensional conformal radiation therapy, *SF-IMRT* static field intensity-modulated radiation therapy

# Planning benchmark study for SBRT of early stage NSCLC Results of the DEGRO Working Group Stereotactic Radiotherapy

Despite the use of various treatment planning systems and planning techniques, almost all SBRT treatment plans met the criteria of the DEGRO practice guidelines: prescription dose of 3 fractions of 15 Gy to the PTV encompassing 65% isodose line, which should achieve identical tumor control probability (TCP), while keeping the OAR

This is very different from the Italian study [23] where no guidelines and fewer constraints were provided and TCP



# To be or not to be homogeneous?

# Time for crowd knowledge-based approach in SBRT planning

Pietro Mancosu<sup>1</sup> · Marco Esposito<sup>2</sup> · Francesca Giglioli<sup>3</sup> · Michele Stasi<sup>4</sup> · Italian medical physicist SBRT working group

	Italian Study	German Study	
Prescription	54 Gy in 3 fr	45 Gy in 3 fr	
	Not defined	65% isodose (i.e.	
Normaliz	V95%>95%	min dose=45Gy)	
Dmax	Not defined	69.2 Gy	

We can conclude that setting the isodose line to a specific value was not enough to homogenize dose distribution in SBRT plans, and new approaches are needed. The im-

HUMANITAS

# To be or not to be homogeneous?


# Time for standardization of SBRT planning through large scale clinical data and guideline-based approaches

HUMANITAS

TRAHI FN

(CTV: clinical target volume) or a combination of all, we fully agree with Mancosu et al. that further homogenization for treatment planning with inhomogeneous dose distributions is desperately needed through controlling and reporting of not only one but multiple target dose parameters and through the general concept of ALARA (as low as reasonably achievable) for critical organ optimization rather than just meeting known dose limitations. This multiple target parameter reporting concept for SBRT is covered in the recently published ICRU 91 report [9]. Finally, we also strongly agree with Mancosu et al. that the plan quality levels needs to be homogenized as well, ideally through multi-institutional multi-platform treatment planning stud-

# ICRU91 - Where to normalize the dose



HUMANITAS



# ICRU REPORT No. 91

# PRESCRIBING, RECORDING, AND REPORTING OF STEREOTACTIC TREATMENTS WITH SMALL PHOTON BEAMS

THE INTERNATIONAL COMMISSION ON RADIATION UNITS AND MEASUREMENTS (Published July, 2017)

# ICRU 91




7. Prescribing, Recording, and Reporting							
	7.1 ICRU Reporting Levels						
	7.2	ose Prescription in SRT					
		7.2.1 Recommendation for Prescription in SRT					
	7.3	Reporting in SRT					
		7.3.1 Recommendation for Reporting at Level 2					
		7.3.2 Discussion and Rationale of Level 2 Reporting					
		7.3.2.1 Dose-volume specification					
		7.3.2.2 Dose-volume reporting specific to OAR and PRV					
		7.3.2.3 Dose homogeneity					
		7.3.2.4 Dose conformity					
		7.3.3 Reporting at Level 3.					
		7.3.3.1 Reporting integral dose					
		7.3.3.2 Biology-based evaluation metrics					
	Reporting of Software Versions for Treatment Planning and Delivery .						
	7.5						

This report does not recommend any particular value of  $D_{\rm V}$  for a prescription. However, the median dose,  $D_{50\%}$ , is likely to be a good measure for a typical dose in a relatively homogeneously irradiated tumor, has been shown to be computed accurately


# ICRU91 - Where to normalize the dose

# ICRU 91

# 50 Gy prescribed to NO INDICATION







**HUMANITAS** 

CANCER CENTER

Report of :  $D_{98\%}$   $D_{50\%}$  $D_{2\%}$ 

Maniella problem				
Criterion 1	Criterion 2			
PTV: maximize Dmin	OAR: reduce Dmax			
PTV: minimize Dmax	PTV: maximize Dmean			
PTV: minimize Dmax	Body: reduce D50%			

# ICRU91 - Where to normalize the dose


# a. Dose [Gy] 60 b. 30 45 75 100 15 80 Ratio of Total Structure Volume [%] 60 40 20 0 20 40 60 80 Relative dose [%] 100 120

Gradient index: PTVmin/BodyD50 Hom. index: (PTVmin-PTVmax)/PTVmean



Multiplanning SBRT lung study 28 centers involved

HUMANITAS




Open questions: Density dishomogeneity Target motion (...)

Mancosu, ESTRO 2013

# Multiplanning: spinal metastases

# SBRT planning for spinal metastasis: indications from a large multicentric study

Marco Esposito<sup>1</sup> (b) · Laura Masi<sup>2</sup> · Margherita Zani<sup>2</sup> · Raffaela Doro<sup>2</sup> · David Fedele<sup>3</sup> · Cristina Garibaldi<sup>4</sup> · Stefania Clemente<sup>5</sup> · Christian Fiandra<sup>6</sup> · Francesca Romana Giglioli<sup>7</sup> · Carmelo Marino<sup>8</sup> · Laura Orsingher<sup>9</sup> Serenella Russo<sup>1</sup> · Michele Stasi<sup>10</sup> · Lidia Strigari<sup>11</sup> · Elena Villaggi<sup>12</sup> · Pietro Mancosu<sup>13</sup>



- a. To recruit a large number of centres equipped with various TPS and delivery systems
- b. To evaluate the compliance of plans to the protocol and to help in the re-planning of non-acceptable plans
- c. To assess the correlation between dosimetric results and planning/delivery parameters
- d. To quantify plan quality using an ad hoc-defined quality score index and to measure plan quality variability between centres

# 43 TPS from 38 centers





HUMANITAS CANCER CENTER

# Spinal metastases - Materials

Prescription dose (PD): 30Gy in 3 fractions.

Planning objective: >90% of the PTV with PD; >80% minor violation.

Planning constraints (from AAPM 101):

PRV cord: V18Gy<0.35cm<sup>3</sup>, V21.9 Gy<0.03cm<sup>3</sup>; Heart: V24Gy<15cm<sup>3</sup>,V30Gy<0.03cm<sup>3</sup>; Esophagus: V17.7 Gy<5cm<sup>3</sup>, V25.2 Gy<0.03cm<sup>3</sup>; Stomach: V16.5 Gy<10cm<sup>3</sup>, V22.2 Gy<0.03cm<sup>3</sup>; Bowel: V16.5 Gy<5cm<sup>3</sup>; V25.2 Gy<0.03cm<sup>3</sup>.

As a last option, planners were allowed to decrease the prescription dose to 27Gy to fulfill all OAR constraints.




# Spinal metastases - Results

In the first analysis, 12.5% of plans (12/96) failed to meet the minimum protocol requirements

Ten of 12 plans were successfully re-optimized using the information coming from more skilful planners

Quality index parameter:

 $(D_{98\%}$ -PTV/ D0.03cm<sup>3</sup> x PRV midollo)\*1/nC.I.





HUMANI LA

# Power is nothing without control


### POWER IS NOTHING WITHOUT CONTROL



RONALDO

HUMANITAS

CANCER CENTER



Name and Address of the Station Station Test of States

IF YOU'RE GOINS TO DRIVE, DRI



The P3000 Energy. Excellent grip, drivability and a reduction in rolling resistance to improve fuel consumption. All this at no extra cost means you can do the saving while Ronaldo does the scoring.





# Ongoing project





### VIRTUAL AUDIT CONCEPT






# https://sbrtvirtualaudit.it/


# How good is a SBRT plan?








L. Rossi et al. Acta Oncol. 2018








# Small and Big




# New imaging possibilities


HUMANITAS CANCER CENTER



# Small fields

broad photon field





volume

Lateral charged particle loss



# Small field output factors evaluation with a microDiamond detector over 30 Italian centers


Serenella Russo<sup>a,\*</sup>, Giacomo Reggiori<sup>b</sup>, Elisabetta Cagni<sup>c</sup>, Stefania Clemente<sup>d</sup>, Marco Esposito<sup>a</sup>, Maria Daniela Falco<sup>e</sup>, Christian Fiandra<sup>f</sup>, Francesca Romana Giglioli<sup>g</sup>, Marco Marinelli<sup>h</sup>, Carmelo Marino<sup>i</sup>, Laura Masi<sup>j</sup>, Maria Pimpinella<sup>k</sup>, Michele Stasi<sup>1</sup>, Lidia Strigari<sup>m</sup>, Cinzia Talamonti<sup>n</sup>, Elena Villaggi<sup>o</sup>, Pietro Mancosu<sup>b</sup>


# 27 centers

Output factor (5-100mm) Square fields with jaws Phase 1: Own detector Phase 2: Common detector

Phase 2: Common detector (diamond)

HUMANITAS





# Small fields



Making Cancer History\*




JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 13, NUMBER 5, 2012

# The Radiological Physics Center's standard dataset for small field size output factors


David S. Followill,<sup>1a</sup> Stephen F. Kry,<sup>1</sup> Lihong Qin,<sup>2</sup> Jessica Leif,<sup>1</sup> Andrea Molineu,<sup>1</sup> Paola Alvarez,<sup>1</sup> Jose Francisco Aguirre,<sup>1</sup> and Geoffrey S. Ibbott<sup>1</sup>

Field Size $(cm \times cm)$	Varian 6 MV RPC Institution		Varian 10 MV RPC Institution	
10×10	1.000	1.000	1.000	1.000
6 × 6	0.921 0.929 (0.013) (0.004) [0.9%] (n=64)		0.946 0.953 (0.017) (0.016) [0.7%] (n=9)	
4×4	(0.018) [1.	0.874 (0.021) 3%] =64)	(0.024) [1	0.912 (0.030) 3%] =9)
3 × 3	(0.017) [1.	0.841 (0.025) 7%] =62)	(0.020) [1.2	0.875 (0.025) 2%] =9)
2×2	(0.019)	0.796 (0.031) 3%] =55)	(0.015) [1.8	0.828 (0.019) 8%] =11)



HUMANITAS

ANCER CENTER



HUMANITAS

CANCER CENTER


### **Medical Physics**



# Technical Note: Multicenter study of TrueBeam FFF beams with a new stereotactic diode: Can a common small field signal ratio curve be defined?

Elisabetta Cagni, Serenella Russo, Giacomo Reggiori, Sara Bresciani, David Fedele, Mauro Iori, Carmelo Marino, Barbara Nardiello, Ruggero Ruggieri, Lidia Strigari, and Pietro Mancosu

8 TrueBeam 10 FFF 2400 MU/min Output Factor: 6-50mm Nominal Field Size (NFS) Effective field Size (EFS)




10 mm ± 1mm (i.e. up to 20% differences) 100 mm ± 1mm (i.e. <<1% differences) Jaws intrinsic geometric uncertainty

### **Medical Physics**



# Technical Note: Multicenter study of TrueBeam FFF beams with a new stereotactic diode: Can a common small field signal ratio curve be defined?


Elisabetta Cagni, Serenella Russo, Giacomo Reggiori, Sara Bresciani, David Fedele, Mauro Iori, Carmelo Marino, Barbara Nardiello, Ruggero Ruggieri, Lidia Strigari, and Pietro Mancosu





# Community approach for reducing small field measurement errors: Experience over 24 centres

Cinzia Talamonti <sup>a,\*</sup>, Serenella Russo <sup>b</sup>, Maria Pimpinella <sup>c</sup>, Maria Daniela Falco <sup>d</sup>, Elisabetta Cagni <sup>e</sup>, Stefania Pallotta <sup>a</sup>, Michele Stasi <sup>f</sup>, Pietro Mancosu <sup>g</sup>



Two centres, using Elekta Beam Modulator and Varian linac, showed data points with deviations greater than 5%. They have been crosschecked and the measurements have been redone resulting in a narrower deviation distribution.

### Conclusion

The presented work is a dosimetric study involving 24 Italian radiotheraphy centers, aimed at improving the overall accuracy in radiotherapy by ensuring high quality of dosimetry. The study aims to minimize systematic errors in output factor measurement over different radiotherapy centres. To this purpose adopting a

# Take home message: Sharing of knowledge HUMANITAS

# Letter



# Crowd knowledge based community in radiotherapy

Mancosu P<sup>1</sup>, Baroni G<sup>2</sup>, Alongi F<sup>3</sup>, Esposito L<sup>4</sup>, Stasi M<sup>5</sup>, Strigari L<sup>6</sup>.

This approach could allow one to envision high-skilled therapy centers providing support to those featuring minor experience and could represent an important strategy for the clinical implementation of emerging technologies at high quality levels.



Multicentre treatment planning inter-comparison in a national context: The liver stereotactic ablative radiotherapy case

Marco Esposito <sup>a</sup>, Giulia Maggi <sup>b</sup>, Carmelo Marino <sup>c</sup>, Laura Bottalico <sup>d</sup>, Elisabetta Cagni <sup>e</sup>, Claudia Carbonini <sup>f</sup>, Michelina Casale <sup>g</sup>, Stefania Clemente <sup>h</sup>, Valentina D'Alesio <sup>d</sup>, David Fedele <sup>i</sup>, Francesca Romana Giglioli <sup>j</sup>, Valeria Landoni <sup>k</sup>, Anna Martinotti <sup>1</sup>, Roberta Nigro <sup>m</sup>, Lidia Strigari <sup>k,\*</sup>, Elena Villaggi <sup>n</sup>, Pietro Mancosu <sup>b</sup>



Technical Note: Multicenter study of TrueBeam FFF beams with a new stereotactic diode: Can a common small field signal ratio curve be defined?

Elisabetta Cagni, Serenella Russo, Giacomo Reggiori, Sara Bresciani, David Fedele, Mauro Iori, Carmelo Marino, Barbara Nardiello, Ruggero Ruggieri, Lidia Strigari, and Pietro Mancosu



# Community approach for reducing small field measurement errors: Experience over 24 centres

Cinzia Talamonti <sup>a,\*</sup>, Serenella Russo <sup>b</sup>, Maria Pimpinella <sup>c</sup>, Maria Daniela Falco <sup>d</sup>, Elisabetta Cagni <sup>e</sup>, Stefania Pallotta <sup>a</sup>, Michele Stasi <sup>f</sup>, Pietro Mancosu <sup>g</sup>

# Discussion time



